ArticleFrontiers in cardiovascular medicine2026
The "sentinel stroke": catheter ablation outcomes in patients with atrial fibrillation detected after stroke.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A subset of patients with atrial fibrillation (AF) first present with ischemic stroke. After neurological recovery, catheter ablation (CA) may be considered in arrhythmia clinic. However, outcomes of CA in patients with atrial fibrillation detected after stroke (AFDAS) remain insufficiently characterized compared with people with previously known AF (KAF). Methods: We conducted a retrospective analysis of consecutive patients who underwent catheter ablation between January 2023 and October 2024 in a special arrhythmia ward. Propensity score matching was performed to balance baseline characteristics. Outcome analyses were restricted to the matched cohort. The primary endpoint was freedom from atrial arrhythmia. The key secondary endpoint was a composite of all-cause death, stroke, or cardiovascular rehospitalization. Results: Among 3,417 eligible patients, 232 were included in the matched analysis (48 AFDAS, 184 KAF). AFDAS patients had numerically lower 2-year atrial arrhythmia recurrence rates [14.6% vs. 22.1%; HR 0.70, (95% CI 0.31-1.57); log-rank Conclusion: In this propensity score-matched cohort, CA was associated with comparable efficacy and safety outcomes in AFDAS and KAF patients. Larger prospective studies are needed to further clarify long-term outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.